Highlights

  • Little Green Pharma (ASX:LGP) completed its Merger with Cannatrek in June 2026, significantly expanding its medicinal cannabis operations.
  • The combined group reported pro-forma FY25 Revenue of A$112 million before synergies.
  • Management is targeting A$3 million in cost synergies during the initial integration phase.
  • Integration progress, European expansion and operational efficiency are key areas to monitor.

Little Green Pharma (ASX:LGP) has undergone a major transformation following its merger with Cannatrek, shifting from a smaller medicinal cannabis producer into a larger vertically integrated cannabis business.

The combined company, operating as LGP Cannatrek, now spans cultivation, Manufacturing and distribution across Australia and international markets.

The key focus ahead is whether the merged group can successfully integrate operations, deliver targeted cost savings and convert its expanded scale into sustainable Earnings growth.

Latest Development

In an investor update released alongside its Annual General Meeting in August 2026, Little Green Pharma (ASX:LGP) outlined its three-stage integration plan for the merged business.

The initial 180-day phase focuses on delivering A$3 million in cost synergies across:

  • Manufacturing.
  • Cultivation.
  • Procurement.
  • Corporate functions.

The company is also progressing Capital works at its Danish Facility and establishing regional Leadership teams in Germany and the United Kingdom.

The second stage runs through FY27, with the third stage beginning from FY28.

Company Overview

Little Green Pharma (ASX:LGP) cultivates, manufactures and distributes medicinal cannabis products.

Following the Cannatrek merger, the group operates under the LGP Cannatrek name and describes itself as a pure-play medicinal cannabis business.

The Danish operation includes a GMP-certified cannabis facility in Europe, with approximately 21,500 square metres of cultivation space and 4,000 square metres of post-harvest facilities.

In Australia, the former Cannatrek operations include an AU-GMP certified manufacturing facility.

Across the combined business, the company has 13 brands and more than 100 products, with core brands contributing approximately 75% of sales.

Recent Developments

The merger significantly expanded the company's revenue base.

On a pro-forma FY25 basis, the combined group generated:

  • Revenue of A$112 million.
  • Adjusted EBITDA of A$13 million before synergies.

Little Green Pharma contributed A$36.8 million of revenue and A$2.9 million of adjusted EBITDA for the year ended March 2025.

Cannatrek contributed A$75.5 million of revenue and A$10.1 million of adjusted EBITDA for the year ended June 2025.

The company appointed a group Chief Financial Officer in August 2026 as part of the broader integration process.

Financial and Operational Position

For the June 2026 quarter, which included only one month of combined operations, Little Green Pharma (ASX:LGP) reported customer receipts of A$22.9 million.

Net cash generated from Operating Activities was A$1.8 million.

Cash stood at A$20.6 million at quarter end, with unused financing facilities of A$9.2 million.

Borrowings were reported at A$5.9 million as at June 2026.

Australia currently represents the majority of sales, contributing approximately 84% of revenue, while Europe including the United Kingdom accounted for 16%.

The company also reported export or distribution agreements across more than 11 countries.

What Investors May Watch Next

The delivery of the A$3 million synergy target will be a key measure of merger execution.

With the initial 180-day integration period beginning in June 2026, progress should become clearer through reporting during the December 2026 quarter.

The first full quarter of combined trading will also provide a clearer indication of the group's revenue scale and operating performance.

International expansion remains another area to monitor.

The company has highlighted opportunities in Germany, where it expects a significant patient market, and has indicated progress towards potential product registration in France.

Risks

The Cannatrek merger creates integration risk, and the targeted cost synergies remain management estimates rather than realised savings.

Little Green Pharma (ASX:LGP) operates in a sector where Demand depends heavily on prescribing frameworks, regulatory conditions and healthcare access.

The company is also undertaking capital works in Denmark, creating ongoing Investment requirements.

Pricing pressure across medicinal cannabis markets, competition and foreign exchange movements may affect profitability, particularly as European operations expand.

Key Takeaways

Little Green Pharma (ASX:LGP) has materially changed its scale and operating profile through the Cannatrek merger.

The combined group now has a broader product portfolio, expanded manufacturing capabilities and a larger revenue base.

The next stage will depend on execution: achieving targeted synergies, integrating operations and demonstrating that increased scale can translate into stronger financial performance.